Is Pfizer on the path to indemnity in India? One waits and watches

New Delhi: While a shortage of vaccines remains an element of bother in India, as per three sources, India is very close to  agreeing to offer foreign coronavirus vaccine companies such as Pfizer legal immunity so that it may utilize their doses in the immunization program. “Indemnity will be given,” one of the sources stated. “If one corporation gets it, they all get it.”

In the meantime, Serum Institute of India, a local vaccine company, has sought indemnity from responsibility for its Covid-19 vaccines, arguing that the standards should be the same for all. Notably the government previously said no decision on indemnifying any International or Indian Covid vaccine makers had been made.

“In general, foreign manufacturers expect indemnification. This, they claim, has been the case all throughout the world. We also consulted with other nations and the World Health Organization “Dr. VK Paul, a member of the NITI Aayog (Health) is quoted saying.

In India, Pfizer, Moderna, and J&J vaccines are available.

After infections increased, India welcomed Pfizer, Moderna, and Johnson & Johnson to offer vaccines in April. No agreement has been reached thus far.

One of Pfizer’s other important demands has already been met: the government has dropped a requirement that imported vaccines be tested in the United States.

Reportedly Pfizer vaccinations will be supplied in August.

It is learnt India is negotiating costs of $10-$12 a dosage for Western injections. The Pfizer vaccine has been developed with Germany’s BioNTech that costs 15.5 euros ($18.86) per dosage in the European Union.

The total number of Covid-19 vaccine doses provided as part of the countrywide immunization program has surpassed 24 crores as per Ministry of Health and Family Welfare on Thursday.

नोट: अगर आपको यह खबर पसंद आई तो इसे शेयर करना न भूलें, देश-विदेश से जुड़ी ताजा अपडेट पाने के लिए कृपया The Lucknow Tribune के  Facebook  पेज को Like व Twitter पर Follow करना न भूलें...
Loading...
--------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
E-Paper